UNSPSC 51282950: Sarafloxacin

This classification denotes a quinolone antibiotic with the molecular formula C20H17F2N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RC3WJ907XY, chemically known as 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid but generally known as sarafloxacin, which bears US NIH Compound Identifier 56208. Most nations schedule sarafloxacin under HS 29335995 and SITC 51576. As of Q4 2014, SARAFLOXACIN remains the US FDA Preferred Term for this commodity.

Sarafloxacin bears US NLM identifiers UMLS ID C0050308 and NCI Concept Code C84143. SMILES: C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F.

UNSPSC 51282950 Sarafloxacin is a Commodity code for a specific pharmaceutical product — a fluoroquinolone antibiotic used in veterinary and human medical applications. State and local governments procure sarafloxacin primarily through pharmaceutical cooperative purchasing vehicles and piggyback contracts that allow multiple jurisdictions to leverage existing vendor agreements. The recent opportunities on file show that health departments and county health systems are the primary issuing bodies, typically sourcing sarafloxacin alongside related antibiotics and pharmaceutical inventory through centralized warehouse or direct-supply arrangements. These procurements are structured as fixed-price contracts with extended terms, often 12 to 24 months with renewal options, and are awarded through competitive bidding (IFB or piggyback processes) to pharmaceutical distributors and specialty suppliers.

Recent activity shows limited direct sarafloxacin procurement in the most recent data; the Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC in August 2026 under MMCAP Infuse consortium pricing, though that contract specifically names Doxycycline Hyclate and Ciprofloxacin Hydrochloride rather than sarafloxacin. Seminole County, Florida released an IFB (due July 26, 2026) for Naloxone and drug deactivation systems, which falls outside the sarafloxacin scope. Geographic activity is concentrated in Florida and Illinois based on recent postings. The code shows sparse current activity with limited open solicitations specifically naming sarafloxacin; procurement under this code appears to flow primarily through established cooperative purchasing agreements and piggyback vehicles rather than individual open bids.